Oric Pharmaceuticals (ORIC) Accumulated Expenses (2019 - 2026)
Oric Pharmaceuticals' (ORIC) quarterly Accumulated Expenses came in at $14.9 million in Q1 2026, up 19.42% YoY from $12.5 million in Q1 2025, and up 83.79% on a QoQ basis from $8.1 million in Q4 2025.
Oric Pharmaceuticals (ORIC) Accumulated Expenses (2019 - 2026) Analysis & Trends
Oric Pharmaceuticals (ORIC) has 8 years of Accumulated Expenses data on file, last reported at $14.9 million in Q1 2026.
- Quarterly Accumulated Expenses rose 19.42% year-over-year to $14.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.9 million (up 19.42% YoY) and the FY2025 annual result came in at $8.1 million, up 5.83% from the prior year.
- Accumulated Expenses improved to $14.9 million in Q1 2026, from $8.1 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $17.3 million in Q3 2025 to a low of $2.8 million in Q2 2022.
- A 5-year average of $11.4 million and a median of $12.2 million in 2024 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2022 — Accumulated Expenses jumped 552.89% — and 2024, when it tumbled 63.8%.
- Tracing ORIC's Accumulated Expenses over 5 years: stood at $14.1 million in 2022, then plunged by 53.59% to $6.5 million in 2023, then advanced by 17.14% to $7.6 million in 2024, then rose by 5.83% to $8.1 million in 2025, then soared by 83.79% to $14.9 million in 2026.
- The last three Accumulated Expenses figures came in at $14.9 million (Q1 2026), $8.1 million (Q4 2025), and $17.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Oric Pharmaceuticals | 1.44 Bn | 1.44 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 16.88 Mn |
| Mar 31, 2026 | 14.88 Mn |
| Dec 31, 2025 | 8.09 Mn |
| Sep 30, 2025 | 17.28 Mn |
| Jun 30, 2025 | 14.92 Mn |
| Mar 31, 2025 | 12.46 Mn |
| Dec 31, 2024 | 7.65 Mn |
| Sep 30, 2024 | 17.00 Mn |
| Jun 30, 2024 | 4.11 Mn |
| Mar 31, 2024 | 12.22 Mn |
| Dec 31, 2023 | 6.53 Mn |
| Sep 30, 2023 | 15.21 Mn |
| Jun 30, 2023 | 11.34 Mn |
| Mar 31, 2023 | 12.94 Mn |
| Dec 31, 2022 | 14.07 Mn |
| Sep 30, 2022 | 11.75 Mn |
| Jun 30, 2022 | 2.77 Mn |
| Mar 31, 2022 | 10.93 Mn |
| Dec 31, 2021 | 13.27 Mn |
| Sep 30, 2021 | 1.80 Mn |